The Future of Vaccines for Tuberculosis

Lisa Stockdale; Helen Fletcher

doi:10.1016/j.ccm.2019.07.009

The Future of Vaccines for Tuberculosis

Clin Chest Med. 2019 Dec;40(4):849-856. doi: 10.1016/j.ccm.2019.07.009.

Authors

Lisa Stockdale¹, Helen Fletcher²

Affiliations

¹ Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre and Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: https://twitter.com/LisaStockdale.
² Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. Electronic address: helen.fletcher@lshtm.ac.uk.

PMID: 31731989
DOI: 10.1016/j.ccm.2019.07.009

Abstract

Exciting clinical results from 2 clinical TB vaccine trials were published in 2018. These, plus promising preclinical candidates form a healthy pipeline of potential vaccines against the leading cause of death from a single infectious agent. The only licensed vaccine, the BCG, continues to be an important tool in protecting against severe forms of TB in children, but has not stopped the diseases causing 1.3 million deaths per year. This review provides an overview of the current TB vaccine pipeline, highlighting recent findings, describes work relating to epidemiologic impact of vaccines, and discusses the future of TB vaccine development.

Keywords: BCG; TB; Vaccines.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Humans
Tuberculosis / drug therapy*
Tuberculosis Vaccines / pharmacology
Tuberculosis Vaccines / therapeutic use*

Substances

Tuberculosis Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding